Rishi Gupta
CIK 1537370 · last filed 2026-02-17
Rishi Gupta is a corporate insider who has filed 21 SEC Form 4 insider transactions across 5 companies since 2012. The most recent filing, for IMRA, was dated Feb 17, 2026. Across all open-market trades the lifetime net is −$161.2M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
VRNA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
601 LEXINGTON AVENUE, 54TH FLOOR
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (IMRA) Delisted | Director | 7,663,349 | $14.59 | $111.81M | -$22.88M | 8 | 2026-02-17 |
| Turnstone Biologics Corp. (TSBX) Delisted | Director | 0 | $0.35 | $0 | $5.00M | 4 | 2025-08-08 |
| Verona Pharma plc (VRNA) Delisted | Director | 4,123,091 | $106.91 | $440.80M | -$145.94M | 5 | 2023-05-15 |
| Dimension Therapeutics, Inc. (DMTX) Delisted | Director | 5,397,698 | — | — | $2.60M | 2 | 2016-05-23 |
| CCXI | Director | — | $10.27 | — | $0 | 1 | 2012-06-26 |
Recent Filings
21 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-17 | Enliven Therapeutics, Inc. (IMRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-08-08 | Turnstone Biologics Corp. (TSBX) Delisted | U | −3,099,265 | $0 | EDGAR |
| 2025-02-10 | Enliven Therapeutics, Inc. (IMRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-07-02 | Turnstone Biologics Corp. (TSBX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-05-20 | Enliven Therapeutics, Inc. (IMRA) Delisted | Sell (S) | −1,033,300 | -$22.88M | EDGAR |
| 2024-03-12 | — | Notice (144) | −56,200 | -$894.1K | EDGAR |
| 2024-02-20 | Enliven Therapeutics, Inc. (IMRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-02-15 | Enliven Therapeutics, Inc. (IMRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-10-17 | Turnstone Biologics Corp. (TSBX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-07-24 | Turnstone Biologics Corp. (TSBX) Delisted | Mixed | +3,099,265 | $5.00M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.